Comparing Symmetric Dimethylarginine and Amyloid-β42 As Predictors of Alzheimer's Disease Development

Overview

Journal J Alzheimers Dis Rep

Publisher IOS Press

Date 2024 Jan 16

PMID 38225970

Authors

Max J Goodman

Xin Ran Li

Jennifer Livschitz

Chiang-Ching Huang

Barbara B Bendlin

Elias D Granadillo

Affiliations

Soon will be listed here.

Abstract

Background: Physicians may soon be able to diagnose Alzheimer's disease (AD) in its early stages using fluid biomarkers like amyloid. However, it is acknowledged that additional biomarkers need to be characterized which would facilitate earlier monitoring of AD pathogenesis.

Objective: To determine if a potential novel inflammation biomarker for AD, symmetric dimethylarginine, has utility as a baseline serum biomarker for discriminating prodromal AD from cognitively unimpaired controls in comparison to cerebrospinal fluid amyloid-β42 (Aβ).

Methods: Data including demographics, magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography scans, Mini-Mental State Examination and Functional Activities Questionnaire scores, and biomarker concentrations were obtained from the Alzheimer's Disease Neuroimaging Initiative for a total of 146 prodromal AD participants and 108 cognitively unimpaired controls.

Results: Aβ ( = 0.65) and symmetric dimethylarginine ( = 0.45) were unable to predict age-matched cognitively unimpaired controls and prodromal AD participants. Aβ was negatively associated with regional brain atrophy and hypometabolism as well as cognitive and functional decline in cognitively unimpaired control participants ( < 0.05) that generally decreased in time. There were no significant associations between Aβ and symmetric dimethylarginine with imaging or neurocognitive biomarkers in prodromal AD patients.

Conclusions: Correlations were smaller between Aβ and neuropathological biomarkers over time and were absent in prodromal AD participants, suggesting a plateau effect dependent on age and disease stage. Evidence supporting symmetric dimethylarginine as a novel biomarker for AD as a single measurement was not found.

Citing Articles

The Interplay between Nitrosative Stress, Inflammation, and Antioxidant Defense in Patients with Lichen Planus.

Tampa M, Nicolae I, Ene C, Mitran C, Mitran M, Matei C Antioxidants (Basel). 2024; 13(6).

PMID: 38929109 PMC: 11200615. DOI: 10.3390/antiox13060670.

References

Kinney J, Bemiller S, Murtishaw A, Leisgang A, Salazar A, Lamb B . Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y). 2018; 4:575-590. PMC: 6214864. DOI: 10.1016/j.trci.2018.06.014. View

Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O . CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016; 3(3):154-65. PMC: 4774260. DOI: 10.1002/acn3.274. View

Holmes C . Review: systemic inflammation and Alzheimer's disease. Neuropathol Appl Neurobiol. 2012; 39(1):51-68. DOI: 10.1111/j.1365-2990.2012.01307.x. View

Kantarci K, Senjem M, Lowe V, Wiste H, Weigand S, Kemp B . Effects of age on the glucose metabolic changes in mild cognitive impairment. AJNR Am J Neuroradiol. 2010; 31(7):1247-53. PMC: 2890033. DOI: 10.3174/ajnr.A2070. View

Slaets S, Le Bastard N, Martin J, Sleegers K, Van Broeckhoven C, De Deyn P . Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J Alzheimers Dis. 2013; 36(4):759-67. DOI: 10.3233/JAD-130107. View

Pina-Escudero S, Lopez L, Sriram S, Longoria Ibarrola E, Miller B, Lanata S . Neurodegenerative Disease and the Experience of Homelessness. Front Neurol. 2021; 11:562218. PMC: 7838483. DOI: 10.3389/fneur.2020.562218. View

Mahase E . Alzheimer's disease: Lecanemab gets full FDA approval and black box safety warning. BMJ. 2023; 382:1580. DOI: 10.1136/bmj.p1580. View

Liu S, Liang S, Liu H, Chen L, Sun L, Wei M . Metabolite Profiling of Feces and Serum in Hemodialysis Patients and the Effect of Medicinal Charcoal Tablets. Kidney Blood Press Res. 2018; 43(3):755-767. DOI: 10.1159/000489912. View

Schindler S, Bollinger J, Ovod V, Mawuenyega K, Li Y, Gordon B . High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019; 93(17):e1647-e1659. PMC: 6946467. DOI: 10.1212/WNL.0000000000008081. View

10.

Selley M . Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging. 2003; 24(7):903-7. DOI: 10.1016/s0197-4580(03)00007-1. View

11.

Amft M, Ortner M, Eichenlaub U, Goldhardt O, Diehl-Schmid J, Hedderich D . The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort. Alzheimers Res Ther. 2022; 14(1):60. PMC: 9044878. DOI: 10.1186/s13195-022-01003-w. View

12.

Sierksma A, Lu A, Mancuso R, Fattorelli N, Thrupp N, Salta E . Novel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology. EMBO Mol Med. 2020; 12(3):e10606. PMC: 7059012. DOI: 10.15252/emmm.201910606. View

13.

Mayeux R, Schupf N . Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants. Neurobiol Aging. 2011; 32 Suppl 1:S10-9. PMC: 3233700. DOI: 10.1016/j.neurobiolaging.2011.09.004. View

14.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

15.

Yan Y, Wang C . Abeta42 is more rigid than Abeta40 at the C terminus: implications for Abeta aggregation and toxicity. J Mol Biol. 2006; 364(5):853-62. DOI: 10.1016/j.jmb.2006.09.046. View

16.

Brookmeyer R, Abdalla N . Design and sample size considerations for Alzheimer's disease prevention trials using multistate models. Clin Trials. 2019; 16(2):111-119. PMC: 6442939. DOI: 10.1177/1740774518816323. View

17.

Petersen R, Lopez O, Armstrong M, Getchius T, Ganguli M, Gloss D . Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2017; 90(3):126-135. PMC: 5772157. DOI: 10.1212/WNL.0000000000004826. View

18.

Zecca C, Pasculli G, Tortelli R, DellAbate M, Capozzo R, Barulli M . The Role of Age on Beta-Amyloid Plasma Levels in Healthy Subjects. Front Aging Neurosci. 2021; 13:698571. PMC: 8438760. DOI: 10.3389/fnagi.2021.698571. View

19.

Paley E, Denisova G, Sokolova O, Posternak N, Wang X, Brownell A . Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofibrillary tangles in human cell and mouse models. Neuromolecular Med. 2006; 9(1):55-82. DOI: 10.1385/nmm:9:1:55. View

20.

de Leon M, Pirraglia E, Osorio R, Glodzik L, Saint-Louis L, Kim H . The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer's disease. PLoS One. 2018; 13(2):e0191240. PMC: 5802432. DOI: 10.1371/journal.pone.0191240. View